|
rs1040411
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Recent GWAS study identified rs4946728 and rs1040411 noncoding SNPs located between PRDM1 and ATG1 genes on chromosome 6q21 as risk factors for secondary malignancies in patients formerly treated with radiotherapy for pediatric Hodgkin disease.
|
24306881 |
2014 |
|
rs10420252
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Two SNPs in COX6B1 (complex IV) were associated with lymph node metastasis in a dominant model (rs6510502, OR = 1.75, 95% CI 1.20-2.57; rs10420252, OR = 1.68, 95% CI 1.11-2.53); rs6510502 was associated also with distant metastasis (OR = 1.67, 95% CI 1.09-2.56 in a dominant model).
|
22545919 |
2012 |
|
rs1042522
|
|
|
0.030 |
GeneticVariation |
BEFREE |
No associations were found among the SNP309, Arg72Pro, risk of CM, age at diagnosis and presence of metastasis in total subjects and when stratified according to the gender.
|
20535124 |
2010 |
|
rs1042522
|
|
|
0.030 |
GeneticVariation |
BEFREE |
BRCA2 methylation frequency was 44%, p53 Pro22 allele frequency was 32% and heterozygous frequency of Arg/Pro72 genotype was 60% which could be associated as risk factor for metastasis (p = 0.046 OR = 4.190).
|
25027116 |
2014 |
|
rs1042522
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Genetic polymorphisms in the 3'UTR region of the CXCL12 (rs1801157) and TP53 codon 72 (rs1042522) genes may contribute to susceptibility to childhood ALL because they affect some important processes, such as metastasis regulation and tumor suppression.
|
23653000 |
2013 |
|
rs1047781
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The rs1047781 (chr19- FUT2) (A/T) was associated with elevated sCEA levels, and rs8176746 (chr9- ABO) was associated with the regional lymph metastasis in the CRC patients.
|
24941225 |
2014 |
|
rs104894228
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The HRAS c.37G>C mutation was also found in 8 of 8 associated secondary tumors.
|
22683711 |
2012 |
|
rs1049074086
|
|
|
0.010 |
GeneticVariation |
BEFREE |
S100P has been shown to mediate tumor growth, metastasis and invasion through the binding of Ca(2+) ions, receptor for advanced glycation end products, cytoskeletal protein ezrin, calcyclin-binding protein/Siah-1-interacting protein and cathepsin D. S100P could potentially serve as diagnostic marker, prognostic/predictive indicator and therapy target for different carcinomas.
|
21947242 |
2012 |
|
rs10491121
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In addition, compared with AA carriers, those carrying the AG + GG genotype at SNP rs10491121 were at lower risk of developing distant metastasis, while the presence of the AT genotype at SNP rs1719153 increased the likelihood of pathologic grade (G3 or G4) disease.
|
30123055 |
2018 |
|
rs1051660
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We detected significant association of the rs1051660 adjusted on metastasis and pain (<i>P</i>=0.02), no other association has been detected between the 7 polymorphisms screened and the dose of morphine needed for pain relief.
|
29259946 |
2017 |
|
rs1052667
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Moreover, rs1052667 polymorphism was correlated with such pathological features of osteosarcoma as tumor size, tumor grade, and tumor metastasis.
|
25136583 |
2014 |
|
rs1053129
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Also patients homozygous for the G allele of rs1053129 in the dihydrofolate reductase (DHFR) gene were more likely to have a metastasis (45%, P= 0.005), and the methylenetetetrahydrofolate reductase (MTHFR) 677C allele was associated with higher degree of liver toxicity (88%, P=0.007).
|
25778468 |
2015 |
|
rs1056123575
|
|
|
0.010 |
GeneticVariation |
BEFREE |
From this analysis, we show that the Cav-1(P132L) expression signature contains numerous genes that have been previously associated with cell migration, invasion, and metastasis.
|
19395651 |
2009 |
|
rs1056629
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We found that the rs1056629 polymorphism interfered with the interaction between MMP9 mRNA and miR-491 and is associated with the metastasis of OS cells.
|
27023472 |
2016 |
|
rs1057519695
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The primary tumor and all the available metastases exhibited the same molecular oncogenic markers (namely, the RAS mutation p.Q61R and the telomerase promoter mutation C228T).
|
28781658 |
2017 |
|
rs1057519710
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Sequence analysis revealed K642E and D820Y mutations in two metastases.
|
19035443 |
2009 |
|
rs1057519783
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In another case, EML4-ALK fusion detected in the primary tumor was associated with ALK G1202R secondary resistance mutation in the post-treatment metastasis.
|
30946933 |
2019 |
|
rs1057519816
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Another patient with the S310F mutation had an apocrine carcinoma with seven lymph nodes positive for metastasis, classified as HER2 3+ by the HercepTest, but which was FISH-negative, as well as ER-negative and PgR-negative.
|
26642960 |
2016 |
|
rs1057519824
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Distant metastasis-free survival (P = 0.008) was associated with MET Y1253D.
|
19639388 |
2009 |
|
rs1057519824
|
|
|
0.020 |
GeneticVariation |
BEFREE |
The Y1235D mutation identified in metastases was shown to induce constitutive activation and a motile-invasive phenotype on transduced carcinoma cells.
|
16245927 |
2005 |
|
rs1057519834
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The primary tumor and all the available metastases exhibited the same molecular oncogenic markers (namely, the RAS mutation p.Q61R and the telomerase promoter mutation C228T).
|
28781658 |
2017 |
|
rs1057519847
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Furthermore, retrospective analysis of 121 patients with lung adenocarcinoma to examine associations between serum SFTPD levels and clinical outcome indicated that in TKI-treated patients with lung cancer harboring EGFR mutations, including Ex19del or L858R, high serum SFTPD levels correlated with a lower number of distant metastases and prolonged overall survival and progression-free survival.
|
28745320 |
2017 |
|
rs1057519847
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Eligible participants were adults (> 18 years) with NSCLC and EGFR mutations (exon 19 deletion or L858R mutation in exon 21) with no history of chemotherapy for metastatic disease (neoadjuvant or adjuvant chemotherapy ending ≥ 6 months before study entry was allowed).
|
22285168 |
2012 |
|
rs1057519847
|
|
|
0.040 |
GeneticVariation |
BEFREE |
No significant differences in pathological stage and metastasis status were found between EGFR wild-type and mutated cases, although EGFR mutation type was related to pathological type (p=0.00) - 19-del, L858R and other mutation types respectively occurred in 34.2%, 42.5% and 23.3% of adenocarcinomas, but in 14.3%, 0% and 85.7% of non-adenocarcinomas.
|
27039821 |
2016 |
|
rs1057519847
|
|
|
0.040 |
GeneticVariation |
BEFREE |
The 19del and L858R patients were similar regarding recurrent patterns, except on pleural/chest wall metastasis (26.0% vs. 12.2%, p = 0.007).
|
29026990 |
2018 |